These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 34015363)

  • 21. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
    van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
    Front Immunol; 2021; 12():781280. PubMed ID: 34987509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Coming of Age of Nucleic Acid Vaccines during COVID-19.
    Rando HM; Lordan R; Kolla L; Sell E; Lee AJ; Wellhausen N; Naik A; Kamil JP; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092822. PubMed ID: 36861992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 vaccine and the cold chain implications for global adoption.
    Das MK
    Indian J Public Health; 2021; 65(3):307-310. PubMed ID: 34558497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19: Coronavirus Vaccine Development Updates.
    Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
    Front Immunol; 2020; 11():602256. PubMed ID: 33424848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.
    Flanagan KL; Best E; Crawford NW; Giles M; Koirala A; Macartney K; Russell F; Teh BW; Wen SC
    Front Immunol; 2020; 11():579250. PubMed ID: 33123165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the road to ending the COVID-19 pandemic: Are we there yet?
    Case JB; Winkler ES; Errico JM; Diamond MS
    Virology; 2021 May; 557():70-85. PubMed ID: 33676349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
    Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
    Front Immunol; 2021; 12():771242. PubMed ID: 34880867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
    Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
    Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.